Blood cancers

Subcut daratumumab: reducing treatment burden in myeloma

Subcutaneous daratumumab with pomalidomide and dexamethasone (D-Pd) is an effective and convenient treatment for patients with relapsed or refractory multiple myeloma who have received at least one line of therapy, including lenalidomide and a proteasome inhibitor. Speaking at the 62nd ASH Annual Meeting, Professor Meletios Dimopoulos presented the findings of the phase 3 APOLLO study ...

Already a member?

Login to keep reading.

© 2021 the limbic